Participant flow

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer · Source last updated 2022-09-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days.

   id

   FG000

   title

   Cetuximab

2. description

   Panitumumab 6 mg/kg IV every 14 days.

   id

   FG001

   title

   Panitumumab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         0

      type

      Ineligibility determined

   2. reasons

      1. group Id

         FG000

         num Subjects

         19

      2. group Id

         FG001

         num Subjects

         20

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         17

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         391

      2. group Id

         FG001

         num Subjects

         384

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         504

      2. group Id

         FG001

         num Subjects

         506

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         500

      2. group Id

         FG001

         num Subjects

         499

      type

      Received Treatment

   3. achievements

      1. comment

         Indicates participants continuing in study

         group Id

         FG000

         num Subjects

         78

      2. comment

         Indicates participants continuing in study

         group Id

         FG001

         num Subjects

         85

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         426

      2. group Id

         FG001

         num Subjects

         421

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

First patient enrolled on 2nd February 2010 and last patient enrolled 19 July 2012. Results are reported as of the data cut-off date of 5 February 2013.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice